Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30186060 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CYP3A4GLANQO2IDO1 | |
| SCHEMBL914310 | 0.84 | ALDH1A1 (0.52) | ALDH1A1CYP3A4GLANQO2IDO1 | |
| SCHEMBL10857430 | 0.82 | ALDH1A1 (0.52) | ALDH1A1IDO1HTTKAT2BMAPK1 | |
| SCHEMBL2082959 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CYP3A4IDO1HTTMAPK1 | |
| SCHEMBL27609025 | 0.82 | IDO1 (0.47) | ALDH1A1CYP3A4IDO1HTTKAT2B | |
| SCHEMBL116805 | 0.80 | ALDH1A1 (0.43) | ALDH1A1CYP3A4GLANQO2IDO1 | |
| SCHEMBL31073706 | 0.80 | ALDH1A1 (0.45) | ALDH1A1CYP3A4GLANQO2IDO1 | |
| SCHEMBL2405141 | 0.80 | ALDH1A1 (0.47) | ALDH1A1CYP3A4GLANQO2IDO1 | |
| SCHEMBL1028847 | 0.80 | ALDH1A1 (0.48) | ALDH1A1CYP3A4IDO1HTTKAT2B | |
| SCHEMBL7408717 | 0.80 | ALDH1A1 (0.45) | ALDH1A1CYP3A4GLANQO2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739307-A2 | TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY | The General Hospital Corporation (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4126879-B1 | N-PHENYL SUBSTITUTED INDOLE DERIVATIVES AS MYT1 INHIBITORS FOR THE TREATMENT OF CANCER | REPARE THERAPEUTICS INC (CA) | 2026-01-21 | — | — | EP | disclosed |
| US-12435090-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | REPARE THERAPEUTICS INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025010291-A2 | TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY | THE GENERAL HOSPITAL CORPORATION (US) | 2025-01-09 | — | — | WO | disclosed |
| WO-2024230647-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2024-11-14 | — | — | WO | disclosed |
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | SINAI HEALTH SYSTEM (CA) | 2024-06-27 | — | — | US | disclosed |
| CN-117729920-A | Carboxamide pyrrolopyrazines and pyridine compounds useful as MYT1 inhibitors and their use in the treatment of cancer | 修复治疗公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-117586252-A | Amide and urea compounds and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2012151355-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-08 | — | — | WO | disclosed |
| EP-2178840-B1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL SA (ES) | 2011-12-14 | — | — | EP | disclosed |
| US-20110212945-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2011-09-01 | — | — | US | disclosed |
| EP-2178840-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | Almirall, S.A. (ES) | 2010-04-28 | — | — | EP | disclosed |
| EP-2100881-A1 | Pyrimidyl- or pyridinylaminobenzoic acid derivatives | Laboratorios Almirall, S.A. (ES) | 2009-09-16 | — | — | EP | disclosed |
| WO-2009021696-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2009-02-19 | — | — | WO | disclosed |
| EP-1718645-A1 | 2-(PYRIDIN-3-YLAMINO)-PYRIDO 2,3-D PYRIMIDIN-7-ONES | Warner-Lambert Company LLC (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082903-A1 | 2-(PYRIDIN-3-YLAMINO)-PYRIDO[2,3-D]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050182078-A1 | 2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones | WARNER-LAMBERT COMPANY, LLC | 2005-08-18 | — | — | US | disclosed |
| EP-0013145-A2 | Substituted anilinopyridines, processes for their preparation and intermediates for use therein, compositions and herbicidal use thereof | ICI AUSTRALIA LIMITED (AU) | 1980-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435090-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | PLK1, CSNK1A1, CSNK1G1 | ALDH1A1 4093/4885CYP3A4 3033/4885GLA 3853/4885 |
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | WEE2, WEE1, KAT2A | ALDH1A1 1899/4885CYP3A4 3438/4885GLA 4131/4885 |
| US-20050182078-A1 | 2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones | CDK2, CDK4, CDK1 | ALDH1A1 1787/4885CYP3A4 1629/4885GLA 3586/4885 |
| US-20110212945-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | DHODH, DPYD, DLD | ALDH1A1 82/4885CYP3A4 613/4885GLA 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.